The use of a large number of cardiovascular biomarkers, meant to complement the use of
the electrocardiogram, echocardiography cardiac imaging, and clinical symptom …

Soluble suppression of tumorigenicity-2 (sST2) is a biomarker widely investigated during the
last few years. Its role has become clear in pathological conditions such as fibrosis and …

Natriuretic peptides have been at the forefront of biomarker use in heart disease and have
been universally recommended as the ideal biomarker in the setting of heart failure. Soluble …

Backgrounds Prognostic value of soluble suppression of tumorigenecity (sST2), a novel
circulating biomarker for myocardial fibrosis, remains elusive in the heart failure patients with …

The natural history of heart failure (HF) is not linear, because changes in the heart structure
and function start long before the disease becomes clinically evident. Many different …

Aims Soluble suppression of tumourigenicity 2 (sST2) and catestatin (CST) reflect
myocardial fibrosis and sympathetic overactivity during the acute worsening of heart failure …

Background Soluble suppression of tumorigenicity-2 (sST2) is a novel biomarker shown to
be useful for prognostic assessment in heart failure (HF). However, very limited data exists …

Background Acute myocardial infarction (AMI) is a leading cause of death worldwide. The
first hours of acute myocardial infarction are correlated with the highest risk of death …

Background ST2, a receptor of interleukin-33, is involved in inflammation. We discerned the
relationship between serum soluble ST2 (sST2) concentrations, inflammation, severity and …

A magnetic beads (MB)-involved amperometric immunosensor for the determination of ST2,
a member of the IL1 receptor family, is reported in this work. The method utilizes a sandwich …